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Aggregation and accumulation of the microtubule-associated protein tau are associated with
cognitive decline and neuronal degeneration in Alzheimer's disease and other tauopathies. Thus,
preventing the transition of tau from a soluble state to insoluble aggregates and/or reversing the
toxicity of existing aggregates would represent a reasonable therapeutic strategy for treating these
neurodegenerative diseases. Here we demonstrate that molecular chaperones of the heat shock
protein 70 (Hsp70) family are potent inhibitors of tau aggregation in vitro, preventing the
formation of both mature fibrils and oligomeric intermediates. Remarkably, addition of Hsp70 to a
mixture of oligomeric and fibrillar tau aggregates prevents the toxic effect of these tau species on
fast axonal transport, a critical process for neuronal function. When incubated with preformed tau
aggregates, Hsp70 preferentially associated with oligomeric over fibrillar tau, suggesting that
prefibrillar oligomeric tau aggregates play a prominent role in tau toxicity. Taken together, our
data provide a novel molecular basis for the protective effect of Hsp70 in tauopathies.
Tau is a microtubule-associated protein predominantly expressed in axons where it is
involved in the maintenance and stabilization of microtubules.1 Under physiological
conditions, tau is a soluble protein with limited secondary structure.2 However, in
Alzheimer's disease (AD), tau dissociates from microtubules and self-associates to form
both fibrillar and prefibrillar oligomeric aggregates.3,4 Aggregated forms of tau are also
found in various other tauopathies, including Pick's disease, corticobasal degeneration, and
progressive supranuclear palsy.5 Importantly, the identification of mutations in the tau gene
that cause hereditary tauopathies demonstrates that tau dysfunction is sufficient to cause
neuronal degeneration.
Neurofibrillary tangles (NFTs), a pathological hallmark of AD and other tauopathies, are
composed of fibrillar tau aggregates and positively correlate with cognitive decline.6
However, recent evidence suggests that prefibrillar oligomeric tau aggregates may represent
the main toxic species.7 For instance, neurodegeneration occurs in some tau overexpression
animal models that lack overt neurofibrillary pathology.8,9 Another study demonstrated that
levels of early multimeric tau aggregates that preceded neurofibrillary pathology correlated
better with memory deficits.10 Moreover, suppression of tau expression improved memory
function without affecting existing NFTs.11,12
The exact mechanisms underlying tau toxicity remain a matter of debate. However, recent
experiments demonstrated that abnormal activation of kinase-based pathways and disruption
of fast axonal transport (FAT) represent toxic gains of function associated with aggregated
but not soluble tau species.13–15 Specifically, experiments in isolated squid axoplasm
revealed that aggregated tau activates a protein phosphatase 1 (PP1) and glycogen synthase
kinase 3 (GSK3)-dependent signaling pathway that results in the inhibition of conventional
kinesin-dependent anterograde FAT.13 Given that aggregated tau pathology is a common
denominator in several neurodegenerative diseases and that tau aggregates are demonstrably
toxic, it follows that prevention of tau aggregation represents a reasonable therapeutic
objective.
Molecular chaperones make up a highly conserved family of related proteins that prevent
protein misfolding and aggregation. Chaperone involvement has been implicated in several
neurodegenerative diseases, including Parkinson's disease, Huntington's disease, and
AD.16–20 In particular, molecular chaperones of the Hsp70 family are upregulated in AD
and attenuate toxicity in a variety of neurodegenerative disease models.21 Hsp70 has been
found to facilitate microtubule binding of tau and is associated with decreased levels of
insoluble tau.22,23 In addition, Hsp70 facilitates the degradation of insoluble tau aggregates
via a direct interaction with CHIP (carboxyl terminus of the Hsc70-interacting protein), a
ubiquitin ligase,23 or BAG2 (BCL2-associated athanogene 2), a cochaperone.24 Taken
together, the available data suggest that Hsp70 attenuates tau toxicity by maintaining tau in a
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soluble, nonaggregated state and by facilitating the degradation of aggregated tau species.
However, the exact tau aggregate species targeted by Hsp70 chaperones remains unknown.
Moreover, specific cellular processes protected by Hsp70 chaperones have not been
identified, and thus data showing reduction of tau toxicity remain largely correlative.
In this study, we demonstrate that Hsp70 directly inhibits tau aggregation by a mechanism
involving preferential associations with soluble, monomeric and prefibrillar oligomeric tau
species. In addition, Hsp70 prevents the toxic effect of preformed tau aggregates on
anterograde FAT. When added to preformed tau aggregates in vitro, Hsp70 did not
appreciably dissociate tau filaments. Interestingly, Hsp70 was found to associate
preferentially with oligomeric versus fibrillar tau aggregates, suggesting that oligomeric
aggregates may represent the main toxic species associated with aggregated tau.
EXPERIMENTAL PROCEDURES
Recombinant Protein Expression and Purification
hTau40, the longest isoform of tau, consists of 441 amino acids and contains both
alternatively spliced N-terminal exons and four microtubule binding repeats (MTBRs). This
is the isoform of tau utilized unless otherwise indicated. hTau23, the shortest canonical
isoform of tau lacking the alternatively spliced N-terminal exons and the second MTBR,
was used when specified. Tau was expressed in Escherichia coli and purified by means of a
polyhistidine tag followed by size exclusion chromatography as previously described.25,26
Mass Spectrometry
Recombinant tau preparations were separated by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE) using 4 to 15% linear gradient polyacrylamide gels and
stained with Coomassie Blue R-250. Bands of interest were excised, and proteins were
digested in situ with trypsin (Promega Corp.). High-performance liquid chromatography–
electrospray tandem mass spectrometry (HPLC–ESI-MS/MS) analyses of the digests were
performed on a Thermo Fisher LTQ instrument fitted with a New Objective PicoView 550
nanospray interface. Online HPLC separation of the digests was accomplished with an
Eksigent NanoLC micro HPLC system. Mascot (Matrix Science) was used to search the
uninterpreted CID spectra against the NCBInr protein database. Methionine was considered
as a variable modification. Determination of probabilities of protein identifications and cross
correlation of the Mascot results with X! Tandem were accomplished with Scaffold
(Proteome Software).
Removal of DnaK
DnaK was removed from our recombinant tau protein preparations using ion exchange
chromatography with HiTrap Q cartridges (GE Life Sciences). Protein was loaded onto the
column in 100 mM Tris (pH 7.4). Elution was performed using a 20 column volume
gradient from 0 to 500 mM NaCl.
Hsp70 Binding Assay
His-tagged recombinant hTau40 (4 μM) was incubated with 2 μM Hsp70 (Assay Designs)
in 100 mM Tris (pH 7.4) for 1 h at ambient temperature. TALON metal affinity resin
(Clontech; 2 μL) in binding buffer [final buffer concentrations of 80 mM Tris (pH 7.5), 450
mM NaCl, 4.5 mM imidazole, and 10% glycerol] was added and incubated for 4 h with
rotation at 4 °C. Samples were centrifuged at 800g for 10 min at 4 °C, and the supernatant
was removed. The resin was subjected to five 10 min washes with 10 mM Tris (pH 8.0), 500
mM NaCl, 5 mM imidazole, 10% glycerol, and 0.1% Triton X-100 with rotation prior to
collection by centrifugation. The final pellet containing resin and bound protein was placed
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in Laemmli sample buffer in a boiling water bath for 5 min and centrifuged at 16000g for 1
min, and the supernatant was collected.
In Vitro Polymerization
hTau40 (2 μM) was incubated at room temperature in aggregation buffer [100 mM Tris, 0.1
mM EGTA, and 5 mM DTT (pH 7.4)] unless otherwise indicated. Recombinant DnaK
(Assay Designs; SPP-630) or Hsp70 (Assay Designs; NSP-555) was added to the
polymerization reaction mixtures at the indicated concentrations prior to the addition of AA.
Tau aggregation was induced using 75 μM peroxidase-free arachidonic acid (AA) (Cayman
Chemical). Polymerization was monitored by measuring the intensity of right angle laser
light scattering as described previously.27 Light scattering data from at least three
independent experiments were analyzed. Time course data were fit with curves using a one-
phase exponential association nonlinear regression analysis in GraphPad Prism version 5.0
(GraphPad Software):
where the value of Y ascends from zero to Ymax with a rate constant K and X is the time.
The t1/2 is 0.69 K−1. IC50 values were derived by fitting end point (t = 300 min) light scatter
data with one-phase exponential decay nonlinear regression analysis (GraphPad Prism 5.0):
where the amount of polymer decreases from Ymax to Ymin with a rate constant K.
Tau Aggregate–Hsp70 Sedimentation Assay
Tau aggregation reaction mixtures containing various concentrations of Hsp70 were
incubated for 5 h in the presence of AA. Each sample was sedimented at 270000g and 25 °C
for 30 min to separate aggregates from monomers. To minimize sample loss, the centrifuge
tubes were blocked with bovine serum albumin (BSA) (Thermo Pierce; 2 mg/mL) for 10
min and rinsed with H2O prior to the addition of the aggregation reaction mixtures.
Immunoblots
Recombinant protein samples were separated by SDS–PAGE on 4 to 15% linear gradient
gels and transferred to nitrocellulose membranes as described previously.28 Samples were
probed with polyclonal tau antibody R1 (0.0025 μg/mL),29 an Hsp70 antibody (Stressmarq;
clone C92; 0.2 μg/mL), or a DnaK antibody (AbCam; clone 8E2/2; 0.025 μg/mL). DnaK
immunoreactivity was quantified using the histogram function of Adobe Photoshop 7.0,
using recombinant DnaK (Assay Designs) to make a standard curve.
Electron Microscopy
For immunogold labeling and quantitative analyses, aggregated samples were diluted 1:10 in
50 mM HEPES and 50 mM KCl (pH 7.6) to reduce aggregate clumping. Aggregated tau
samples were placed on 300 mesh Formvar/carbon-coated copper or nickel grids [Electron
Microscopy Sciences (EMS)], and the grids were exposed briefly to 10% glutaraldehyde
(EMS) prior to being rinsed and stained with 2% uranyl actetate (EMS). For immunogold
labeling, grids were blocked with a 0.1% gelatin/5% goat serum (GS) mixture in TBS and
incubated with an anti-Hsp70 (Stressmarq; 50 μg/mL) and/or a His probe (Santa Cruz; 10
μg/mL) primary antibody. Grids were then rinsed with TBS prior to incubation with 10 nm
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(Sigma) or 6 nm (Jackson ImmunoResearch) diameter gold-conjugated anti-mouse IgG and/
or 10 nm gold-conjugated anti-rabbit IgG (Sigma) secondary antibodies diluted 1:20 in a 5%
GS/TBS mixture. Finally, grids were rinsed with 10× TBS to reduce the level of nonspecific
labeling and rinsed with H2O prior to being stained with uranyl acetate.
For quantitative analysis, Optimas 6.0 (Media Cybernetics) was used to measure aggregates
(defined as objects >20 nm in length). A minimum of five fields per grid were analyzed. To
quantify Hsp70 immunogold labeling, aggregated structures were first divided into one of
two groups, those ≤100 nm in length and those >100 nm in length. This cutoff was chosen
because most of the amorphous aggregates were <100 nm in size, whereas the majority of
the mature tau filaments were >100 nm in size (data not shown). Gold labeling for each
group is represented as the number of gold particles that label aggregates in a given group
divided by the total number of aggregates in that group. Results were normalized to the total
number of gold particles per field and multiplied by 100. Gold particles that label <20 nm
aggregates were excluded from the analysis.
Squid Axoplasm Motility Assays
Axoplasm from squid giant axons (Loligo pealii; Marine Biological Laboratory) was
extruded as previously described.30 For these assays, hTau40 (4 μM) was polymerized in 50
mM HEPES, 50 mM KCl, and 5 mM DTT (pH 7.6) using 75 μM AA as an inducer. Hsp70
(Assay Designs) was diluted in 50 mM HEPES and 50 mM KCl (pH 7.6). Preaggregated
hTau40 reaction mixtures or PAD peptide (Genscript)15 with or without Hsp70 (final
concentration of 1.6 μM) was diluted 1:1 in X/2 buffer [175 mM potassium aspartate, 65
mM taurine, 35 mM betaine, 25 mM glycine, 10 mM HEPES, 6.5 mM MgCl2, 5 mM
EGTA, 1.5 mM CaCl2, and 0.5 mM glucose (pH 7.2)] supplemented with 5 mM ATP.
Motility was analyzed using a Zeiss Axiomat microscope equipped with a 100×, 1.3 N.A.
objective and DIC optics. Organelle velocities were measured by matching calibrated cursor
movements to the speed of vesicles moving in the axoplasm.31
Statistics
Sigmastat (Systat Software, Inc.) was used for all statistical tests. Comparisons were made
using a paired t test, an unpaired t test, or one-way ANOVA followed by Student–Newman–
Keuls post hoc analysis. Data were expressed as means ± the standard error of the mean
(SEM), and significance was set as noted. Comparison of transport data from axoplasms
under different conditions was performed using data collected from 40 to 50 min after
perfusion.
RESULTS
Recombinant Tau Protein Directly Interacts with DnaK, a Chaperone of the Hsp70 Family
When preparations of recombinant tau purified from E. coli by means of a 6×-histidine (His)
tag were analyzed by SDS–PAGE, the presence of varying amounts of an ~70 kDa
polypeptide was consistently evident (Figure 1A of the Supporting Information). The 70
kDa protein band was subjected to tryptic digestion, and the peptides obtained were
analyzed via HPLC–ESI-MS/MS. Sequence homology analysis of the vast majority of
peptides obtained revealed the 70 kDa band corresponded to DnaK, a bacterial member of
the Hsp70 family of molecular chaperones.
To determine whether DnaK is universally present in recombinant tau purified from E. coli,
several preparations were tested for DnaK immunoreactivity. DnaK was present in all
preparations of the longest isoform of tau (hTau40) analyzed, as well as in a preparation of
the shortest tau isoform (hTau23), albeit to varying degrees (Figure 1B of the Supporting
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Information). Quantitative immunoblotting analysis indicated that DnaK accounted for
approximately 10.5 ± 0.7% (mean ± standard error) of a given recombinant hTau40
preparation. To determine how Hsp70 family members affect tau aggregation in vitro, we
generated an uncontaminated preparation of recombinant tau. We accomplished this by
performing ion exchange chromatography to purify monomeric tau from that complexed
with DnaK (Figure 1C of the Supporting Information). This purified, DnaK-free tau was
used for all studies unless otherwise specified.
To determine whether DnaK affects tau aggregation, hTau40 (2 μM) was incubated in the
presence of increasing concentrations of recombinant DnaK (Figure 1D of the Supporting
Information). Tau aggregation was induced by the addition of AA and monitored using right
angle laser light scattering (LLS). A dose-dependent decrease in LLS was observed with
increasing concentrations of DnaK, indicative of a reduced level of formation of tau
aggregate. On the basis of the range of DnaK contamination observed in our recombinant
tau preparations, the amount of inhibition expected in a typical tau aggregation reaction
could be estimated. In an aggregation reaction mixture containing 2 μM hTau40, the
concentration of DnaK ranges from 0.10 to 0.26 μM (Figure 3B), corresponding to 19 to
42% inhibition of tau aggregation, respectively, as estimated from the LLS experiments.
These results likely explain the variability we observe in the assembly properties from
different tau preparations (data not shown) and stress the importance of removing this
chaperone prior to in vitro aggregation experiments.
Hsp70 Inhibits Tau Aggregation in Vitro
We next sought to determine whether human Hsp70 (HSPA1A), a chaperone with a
sequence 50% homologous to that of DnaK, similarly interacts with tau to inhibit
aggregation. A His tag-based pull-down assay was used to evaluate direct protein–protein
interactions between purified recombinant hTau40 and Hsp70. His-tagged recombinant tau
was incubated with untagged Hsp70, and the resultant mixture was incubated with TALON
metal affinity resin, which avidly binds to the His tag on tau. After extensive washing, an
imidazole elution was performed. Hsp70 did not bind to TALON resin in the absence of tau,
demonstrating that Hsp70 does not bind the TALON resin nonspecifically. However, when
His-tagged tau is added to the reaction mixture, Hsp70 is detected in the elution fraction
(Figure 1A). These data indicate that members of the Hsp70 family of chaperones directly
bind to soluble monomeric tau, likely because it is a largely unstructured protein.2
To evaluate whether direct interaction of tau with Hsp70 influences tau aggregation, purified
recombinant hTau40 (2 μM) was incubated in the presence of varying concentrations of
recombinant Hsp70, ranging from 15.6 to 500 nM. A dose-dependent reduction in the level
of tau aggregation was observed with increasing Hsp70 concentrations (Figure 1B). The
IC50 for Hsp70 was calculated to be 76 nM, which corresponds to a stoichiometry of one
Hsp70 for every 26 tau macromolecules.a If the primary mechanism of Hsp70 inhibition
consisted of removing monomeric tau from the aggregation reaction mixture, then 96% of
the total tau (>1.9 μM) would still be able to aggregate. Therefore, this substoichiometric
inhibition suggests that Hsp70 may interact with tau aggregates, thus inhibiting further
assembly. Moreover, Hsp70 affects the extent (Ymax) but not the rate (K) of polymerization
(Table 1). This supports a model in which Hsp70 does not appreciably affect nucleation but
prevents additional tau monomers from being incorporated into existing tau aggregates.
As an independent experimental approach, transmission electron microscopy (EM) was used
to verify results from LLS experiments. These experiments confirmed that incubation of tau
with Hsp70 resulted in a dose-dependent reduction in the overall amount of aggregated
material observed per field (Figure 1C). Qualitative analysis revealed that filament length
decreased with an increasing Hsp70 concentration. Moreover, at the highest concentration of
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Hsp70 tested (Hsp70:tau molar ratio of 1:4), filaments were rarely observed while only
small predominantly oligomeric aggregates remained. Hence, Hsp70, though a potent
inhibitor of tau filament formation, appears to be somewhat less effective at inhibiting the
formation of tau oligomers.
To ensure that the oligomeric aggregates observed by EM do not result from Hsp70
aggregation, we co-incubated Hsp70 (2 μM) with AA, using an equimolar concentration of
BSA as an alternative substrate. Hsp70 has been reported to bind albumin with a Kd on the
same order of magnitude as that of tau, and it has already been documented that Hsp70 will
self-associate if no substrate is present.32–34 No aggregates were observed by EM, indicating
that Hsp70 is not aggregating under our experimental conditions. Taken together, these
results demonstrate that Hsp70 directly and potently inhibits tau aggregation in vitro.
As previously reported for Hsp70 inhibition of α-synuclein aggregation,35–37 the inhibition
of tau aggregation promoted by Hsp70 did not require ATP or cochaperones (e.g., Hsp40) as
the experiments presented here were performed in their absence. In fact, the addition of ATP
to the reaction mixture did not significantly affect our findings (data not shown).
Hsp70 Preferentially Associates with Tau Oligomers
The experiments described above demonstrated that Hsp70 directly interacts with soluble
tau. However, because Hsp70 hinders tau aggregation at substoichiometric concentrations, it
follows that Hsp70 may also interact with small oligomeric and/or filamentous tau
aggregates, thereby preventing the further addition of monomeric tau to these aggregates. To
determine whether Hsp70 interacts with tau aggregates, Hsp70/tau mixtures were
sedimented after the addition of AA or ethanol vehicle (Figure 2A). As predicted, both
Hsp70 and tau are found in the supernatant in the absence of AA. However, when AA is
added to the reaction mixture, Hsp70 sediments with tau, indicating Hsp70 binds to some
form of tau aggregate. Moreover, it was previously demonstrated that AA does not sediment
with tau aggregates,38 signifying that Hsp70 does not interact with AA. Immunogold
labeling of Hsp70 was utilized to confirm that Hsp70 appears to associate with tau
aggregates that sediment (Figure 2A).
We have demonstrated that Hsp70 binds tau when added prior to the initiation of
aggregation. We next sought to determine whether Hsp70 preferentially associated with
preformed filamentous and/or oligomeric tau aggregates, as tau assembled in vitro is
composed of a mixture of both. Purified hTau40 (2 μM) was incubated with AA and
aggregated in the absence of Hsp70. Once the reaction reached equilibrium (5 h), an
equimolar concentration of Hsp70 was added. Immunogold labeling of these tau aggregate/
Hsp70 mixtures with an anti-Hsp70 antibody revealed that the vast majority of Hsp70
associates with amorphous oligomeric aggregates, and only occasional labeling was found
on filaments (Figure 2B). In fact, Hsp70 was 3 times more likely to associate with small
oligomeric aggregates (≤100 nm) than filamentous ones (>100 nm) (Figure 2C). Even so,
this is still an overestimation of filament labeling as larger filamentous aggregates possess
far more individual tau proteins with which Hsp70 could potentially interact compared to
oligomeric aggregates. Finally, we verified that these aggregates possess both Hsp70 and tau
using double-label immunogold EM analysis. Amorphous tau aggregates were doubly
labeled with anti-Hsp70 and anti-His antibodies, confirming that Hsp70 preferentially
associates with oligomeric tau aggregates and only occasionally with filamentous aggregates
(Figure 2D). From these data, we concluded that Hsp70 not only prevents tau aggregation
but also binds to preexisting oligomeric tau aggregates.
Though the majority of Hsp70 macromolecules associated with oligomeric aggregates, some
filament labeling was observed. Recent evidence casts doubt on the toxicity of fibrillar tau
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aggregates, suggesting instead that tau oligomers may represent the main neurotoxic species
(reviewed in ref 7). Should Hsp70 promote dissociation of tau filaments into smaller
oligomeric aggregates, this effect could be detrimental to neurons. Thus, we set out to
determine the effect of Hsp70 on preexisting tau filaments. Tau (2 μM) was aggregated for 5
h prior to the addition of an equimolar concentration of Hsp70. After incubation for 24 h,
quantitative EM was performed (Figure 3A,B). No significant difference in the overall mass,
number, or length of tau aggregates was observed (Figure 3C,D). The only detectable effects
were a small but statistically significant decrease in the number of >200 nm tau aggregates.
From these data, we concluded that Hsp70 may have, at most, a mild dissociative effect on a
subset of preformed aggregates.
Hsp70 Abolishes the Effects of Tau Aggregates on Fast Axonal Transport
The data described above demonstrated that Hsp70 avidly binds to oligomeric and, to a
lesser extent, filamentous tau aggregates. On the basis of these data, we evaluated whether
Hsp70 alters the toxic properties of tau aggregates. Our recent work using isolated squid
axoplasm demonstrated that tau aggregates, but not soluble tau monomers, selectively
inhibited anterograde, conventional kinesin-dependent fast axonal transport (FAT), leaving
retrograde, cytoplasmic dynein-dependent FAT unaffected.13 This toxic effect of aggregated
tau on anterograde FAT results from abnormal activation of a PP1–GSK3 signal
transduction pathway that culminates in the phosphorylation of kinesin light chains by
GSK3, and the release of conventional kinesin from its transported cargoes.13,15
Interestingly, these aggregated tau reaction mixtures contain both oligomeric and
filamentous aggregates. Whether oligomer, filaments, or perhaps both forms of tau
aggregates are toxic remains to be determined.
Vesicle motility assays in isolated axoplasm were used to determine whether Hsp70 impacts
the toxicity of tau aggregates on FAT. Hsp70 was incubated with tau aggregates prior to
their addition to the axoplasm, thus allowing Hsp70–tau interactions prior to perfusion. As
previously shown, soluble tau did not affect FAT (Figure 4A), whereas aggregated tau
selectively inhibited anterograde FAT (Figure 4B).13,15 Remarkably, preincubation of
Hsp70 with tau aggregates completely prevented their inhibitory effect on anterograde FAT
(Figure 4C). Additionally, we endeavored to ascertain the effect of Hsp70 alone on axonal
transport. Hsp70 by itself had a mild depressive effect on both anterograde and retrograde
transport (Figure 5A), likely because it is a chaperone that is known to interact with
numerous proteins. Even so, this effect was not observed in the presence of tau aggregates
(Figure 4C), suggesting that Hsp70 is indeed binding tau aggregates very tightly to prevent
their effects on FAT.
As an additional control, we co-incubated Hsp70 with the phosphatase activating domain
(PAD) peptide (amino acids 2–18 of hTau40).13,15 When tau aggregates, it is the exposure
of the PAD domain that activates the PP1–GSK3 signaling cascade, resulting in anterograde
FAT inhibition (Figure 5B).13,15 Because PAD alone is capable of inhibiting anterograde
axoplasmic transport15 and Hsp70 interacts with hydrophobic substrates such as the
VQIVYK and VQIINK hexapeptide motifs in the MTBR region of tau,32 we hypothesized
that Hsp70 would not prevent the toxic effect of PAD on transport. In fact, this was exactly
what we observed. PAD in the presence of Hsp70 still inhibited anterograde FAT beyond
the mild inhibition observed with Hsp70 alone, whereas no additional effect was observed
on retrograde FAT (Figure 5C). Taken together, our results strongly suggest that Hsp70
prevents the toxicity of aggregated tau via a direct interaction with these aggregates. These
results, in conjunction with the immunogold studies that demonstrated that Hsp70
preferentially binds to tau oligomers, advocate that it is, in fact, tau oligomers that are
responsible for the observed effect on FAT.
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Displacement of tau from microtubules allows for its self-association and deposition. In
opposition, molecular chaperones, like the Hsp70 chaperone family, prevent protein
aggregation by binding exposed hydrophobic residues. Though the Hsp70 family has several
members, the two that are predominantly expressed in the cytoplasm are the constitutively
expressed heat shock cognate 70 (Hsc70) and its stress-induced counterpart, Hsp70; their
sequences are 92% homologous (reviewed in ref 39). Co-immunoprecipitation of Hsp70
with tau has been previously reported in various cell lines32,40 as well as human brain
extracts.41 Moreover, it was demonstrated that Hsc70 rapidly associates with tau after
microtubule destabilization.42 Here, we report a direct interaction between Hsp70 and
soluble tau in vitro and demonstrate that this interaction inhibits the self-association of tau
into aggregates. Additionally, we show that Hsp70 also interacts with preexisting tau
aggregates, having a preferential selectivity for oligomeric versus filamentous tau
aggregates. Finally, our studies indicate that binding of Hsp70 to tau aggregates prevented
their toxic effect on FAT. These findings are summarized in Figure 6.
It is highly likely that Hsp70 interacts with tau in a manner similar to that of Hsc70, which
appears to bind to two hydrophobic stretches of the tau protein, VQII and VQIV, located in
the second and third MTBRs, respectively.32 These are the same two motifs discovered to be
essential for tau aggregation.43–46 However, the reported KD values for tau–Hsc70 binding
are more than 100-fold lower than those for tau–tau binding,47 which strongly suggested that
Hsc70 competitively inhibits tau–tau interactions. A previous report indicated that a nearly
mutually exclusive relationship existed between tau neurofibrillary pathology and neurons
that stain strongly for Hsp70 in AD, suggesting a role for Hsp70 in preventing fibrillar tau
agggregation.22 Moreover, Hsp70 was shown to reduce the level of tau aggregation in
several cell lines22,23 and animal models.23,48 Our current studies using highly purified
components indicate that Hsp70 inhibits the formation of tau filaments in a dose-dependent
fashion. The inhibitory effect of Hsp70 on tau aggregation involved interactions of Hsp70
with both soluble tau monomers and oligomeric tau aggregates. Additionally, our work
appears to be consistent with a previous study in which Hsp70 inhibited heparin-induced tau
aggregation in vitro as measured by the decreased fluorescence of thioflavin T (ThT), a dye
that recognizes the β-pleated sheet conformation usually associated with fibril formation;
however, unlike our results, this decrease was not dose-dependent.41 This discrepancy may
be explained by the fact that ThT fluorescence is unable to distinguish between different
forms of aggregation, i.e., oligomeric and filamentous aggregates. As demonstrated here,
even at the highest concentration of Hsp70 tested, oligomeric aggregates persist. The
conspicuous absence of tau fibrils at substoichiometric concentrations of Hsp70 suggests
that the association of Hsp70 with tau oligomers may sequester tau in stable “off-pathway”
aggregates. A similar mechanism has already been proposed for α-synuclein, amyloid β, and
huntingtin;49–51 however, this is the first mechanistic study describing how Hsp70 inhibits
tau polymerization. Further studies are necessary to determine how Hsp70 alters tau's
conformation, ultimately resulting in a decreased level of filament formation.
Our data indicate that Hsp70 alone has little depolymerizing effect on preexisting tau
filaments. Highly ordered amyloid fibrils are very stable, and the hydrophobic binding sites
necessary for Hsp70 interaction are likely buried within the fibril. Though very efficient at
preventing the conformational state that results in fibril formation, Hsp70 alone cannot
readily reverse this conformational shift once it has occurred. However, in vivo,
cochaperones, including Hsp40 and Hsp90, augment Hsp70 activity.52 Thus, it is
conceivable that Hsp70 in combination with other cochaperones may be capable of
rearranging tau filaments. In this regard, our data agree with previously reported studies
indicating that Hsp70 alone cannot rearrange mature Aβ, huntingtin, or α-synuclein
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fibrils.35,49,51 On the other hand, we demonstrate that Hsp70 preferentially interacts with
oligomeric tau aggregates. This suggests that the hydrophobic binding sites for Hsp70 on tau
are more readily available in tau oligomers than in tau filaments. Thus, the MTBR domains,
which form the core of the NFT, are likely more exposed in the oligomer.
Though Hsp70 does not appear to influence the morphology of preformed tau aggregates,
we found that it does attenuate the toxicity of these aggregates. Using vesicle motility assays
in isolated axoplasm, we previously reported that a mixture of oligomeric and filamentous
tau aggregates selectively impaired anterograde FAT. This toxic effect of tau aggregates was
mediated by PP1 and GSK313 and involved an increased level of exposure of a phosphatase
activation domain (PAD), a 17-amino acid sequence located in the amino terminus of tau.15
Interestingly, we found that Hsp70 completely reverses this effect and that this reversal
appears to be mediated by a direct interaction of Hsp70 with aggregated tau. Given that
immunogold labeling of Hsp70 revealed limited labeling of filaments and abundant labeling
of small oligomeric structures, it is likely that tau oligomers are the main species responsible
for inhibition of anterograde FAT, supporting the hypothesis that prefibrillar oligomeric tau
species are more toxic than mature fibrils.7 Furthermore, Hsp70 did not alter the inhibitory
effect of PAD peptide on anterograde FAT, indicating that Hsp70 is not interacting with
PAD, directly leaving us to speculate that the protective effect of Hsp70 on FAT likely
involves a reduction in PAD availability. Obtaining adequate support for this contention,
however, will require further experimentation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Hsp70 forms a complex with tau and inhibits aggregation in vitro. (A) His-tagged hTau40
was incubated with untagged Hsp70 (HSPA1A). Reaction mixtures were incubated with
TALON metal affinity resin, which interacts with the His tag located on tau. Proteins bound
to the resin were immunoblotted for Hsp70 and tau. The Hsp70 alone control confirms that
Hsp70 does not bind nonspecifically to the resin. In the presence of tau, Hsp70 is detected in
the elution fraction. (B) Intensity of right angle light scattering as a function of time. Each
time point is the average of at least three independent experiments and is represented as the
mean ± SEM: (■) Tau alone (2 μM), (◯) 1:128 Hsp70:tau ratio, (▲) 1:64 Hsp70:tau ratio,
(◇) 1:32 Hsp70:tau ratio, (▼) 1:16 Hsp70:tau ratio, (□) 1:8 Hsp70:tau ratio, and (●) 1:4
Hsp70:tau ratio. (C) Representative electron micrographs of aggregation reactions at
equilibrium (t = 300 min). Note the decreased level of formation of filamentous aggregates
while some oligomeric aggregates persist even at the highest concentrations tested. The
scale bar is 500 nm. The bottom right image (–Tau) is Hsp70 in aggregation buffer (+AA) in
the absence of tau.
Patterson et al. Page 14














Hsp70 associates with tau aggregates. (A) Tau was aggregated in the presence of varying
concentrations of Hsp70 for 5 h. After centrifugation, the resulting supernatant (S) and pellet
(P) fractions were analyzed by immunoblotting using anti-Hsp70 and anti-tau antibodies. In
the absence of AA (−AA), both Hsp70 and hTau40 remain in the supernatant fractions.
When AA is added (+AA), Hsp70 cosediments with tau in pellet fractions. Electron
micrographs demonstrate immunogold labeling of Hsp70 on amorphous tau oligomers. The
ratio at the bottom left is the Hsp70:tau ratio. (B) Hsp70 was added to preformed oligomeric
and filamentous tau aggregates. Electron micrographs demonstrate abundant Hsp70
immunogold labeling of oligomeric structures (arrowheads) but very limited labeling of tau
filaments (arrow). (C) Quantification of Hsp70 immunogold labeling. Hsp70 was 3 times
more likely to label ≤100 nm structures than >100 nm structures. *p < 0.01 (Student's t test).
(D) Double immunogold labeling of Hsp70 (arrow) and the His tag on tau. Several
amorphous aggregates were labeled for both. Also shown is a tau filament that is labeled for
Hsp70. Hsp70 is labeled with 6 nm gold particles. His-tagged hTau40 is labeled with 10 nm
gold particles. The scale bars are 50 nm.
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Hsp70 has a modest effect on mature tau filaments. Electron micrographs of (A) preformed
tau aggregates and (B) preformed tau aggregates with Hsp70. The scale bar is 500 nm. (C)
Incubation with Hsp70 did not impact the polymer mass observed per field [p = 0.18
(Student's t test)]. (D) There was a slight decrease in the number of >200 nm aggregates,
indicating that Hsp70 may have a subtle effect on the dissociation of tau filaments. Results
are expressed as the mean ± the standard error of the mean [*p < 0.05 (Student's t tests)].
Patterson et al. Page 16














Hsp70 rescues anterograde FAT in isolated squid axoplasm. Vesicle motility assays in
isolated squid axoplasm. Individual velocity (micrometers per second) rate measurements
(arrowheads) are plotted as a function of time (minutes). Black arrowheads and lines
represent anterograde FAT rates (conventional kinesin-dependent), and gray arrows and
lines represent retrograde FAT rates (cytoplasmic dynein-dependent). (A) Perfusion of
soluble hTau40 (2 μM) in axoplasm does not affect FAT. (B) Perfusion of tau aggregates (2
μM) results in a select inhibition of kinesin-dependent FAT as previously reported.13 (C)
When Hsp70 (1.6 μM) is preincubated with the aggregated tau, no decrease in the velocity
of anterograde FAT is observed [p < 0.001 (unpaired t test)], indicating that Hsp70 reverses
the toxicity of tau aggregates in isolated axoplasm.
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Hsp70 does not rescue anterograde FAT when incubated with PAD peptide. Vesicle motility
assays in isolated squid axoplasm. Individual velocity (micrometers per second) rate
measurements (arrowheads) are plotted as a function of time (minutes). Black and red
arrowheads and lines represent anterograde FAT rates (kinesin-dependent), and gray and
green arrowheads and lines represent retrograde FAT rates (cytoplasmic dynein-dependent).
(A) Perfusion of Hsp70 (1.6 μM) alone in axoplasm has a mild inhibitory effect on both
anterograde and retrograde FAT. (B) Perfusion of PAD peptide (2 μM) results in a select
inhibition of kinesin-dependent FAT as previously reported.15 (C) Co-incubation of Hsp70
(1.6 μM) with PAD peptide does not alter the inhibitory effect of PAD on anterograde FAT
[p = 0.72 (unpaired t test)]. For comparison, dashed lines represent Hsp70 alone as shown in
panel A; note that the green and gray lines representing retrograde transport are coincident
in panel C.
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Model of the effects of Hsp70 on tau dysfunction. Hsp70 binds soluble, monomeric tau that
dissociates from microtubules, thus preventing self-association of tau into oligomeric and/or
filamentous aggregates. In addition, Hsp70 also interacts with tau oligomers, ultimately
preventing the formation of filamentous tau aggregates. Additionally, the association of
Hsp70 with aggregated tau, particularly oligomeric tau aggregates, prevents activation of
PP1 and GSK3 by the tau aggregates, preventing inhibition of conventional kinesin-
dependent fast axonal transport.
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